# Moxonidine for Prevention of Post-ablation AFib Recurrences

> **NCT01791699** · PHASE4 · COMPLETED · sponsor: **Spyridon Deftereos** · enrollment: 150 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Moxonidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01791699
- **Lead sponsor:** Spyridon Deftereos
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-11
- **Final completion:** 2014-04
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2014-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01791699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01791699, "Moxonidine for Prevention of Post-ablation AFib Recurrences". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01791699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*